Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Nordea Investment Management AB

Nordea Investment Management AB boosted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 19.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 67,546 shares of the biotechnology company's stock after purchasing an additional 10,815 shares during the period. Nordea Investment Management AB owned approximately 0.07% of Sarepta Therapeutics worth $8,228,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of SRPT. Sunbelt Securities Inc. lifted its stake in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 232 shares during the last quarter. Huntington National Bank grew its holdings in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 175 shares during the last quarter. Nkcfo LLC bought a new position in shares of Sarepta Therapeutics in the second quarter worth about $43,000. UMB Bank n.a. lifted its holdings in Sarepta Therapeutics by 105.9% during the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock valued at $48,000 after buying an additional 197 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in Sarepta Therapeutics during the 3rd quarter valued at about $59,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Down 1.2 %

Shares of SRPT stock traded down $1.48 during trading hours on Friday, reaching $124.79. 760,694 shares of the company's stock were exchanged, compared to its average volume of 620,115. The stock's fifty day moving average price is $122.11 and its two-hundred day moving average price is $131.33. The stock has a market cap of $11.92 billion, a PE ratio of 99.83 and a beta of 0.77. Sarepta Therapeutics, Inc. has a 1 year low of $102.15 and a 1 year high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SRPT. Royal Bank of Canada reaffirmed an "outperform" rating and set a $182.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 21st. UBS Group lifted their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. Piper Sandler dropped their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 27th. StockNews.com downgraded Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, November 20th. Finally, Robert W. Baird dropped their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a report on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $178.71.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now owns 5,880 shares of the company's stock, valued at $738,234. The trade was a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.